until every animal is well
Accelerating innovation to deliver better treatments
Animol Discovery is accelerating the identification of innovative medicines for unmet needs in animals by using a disruptive approach to small molecule discovery and development. We achieve this by combining genomics analysis, the power of DNA-encoded libraries, and artificial intelligence/machine learning technologies. As a result, Animol Discovery can identify more effective and safer pharmaceuticals which are tailored to the needs of veterinary patients.
Accelerating innovation to deliver better treatments
Animol Discovery is accelerating the identification of innovative medicines for unmet needs in animals by using a disruptive approach to small molecule discovery and development. We achieve this by combining genomics analysis, the power of DNA-encoded libraries, and artificial intelligence/machine learning technologies. As a result, Animol Discovery can identify more effective and safer pharmaceuticals which are tailored to the needs of veterinary patients.
Innovate until every
animal is well
At Animol Discovery we are passionate about the health of animals. Companion and farm animals deserve the best possible medicines, and we are committed accelerating innovation to improve standards of care. Our approach enables the provision of novel treatments for patients substantially faster without compromising on safety and efficacy.
Innovate until every animal is well
At Animol Discovery we are passionate about the health of animals. Companion and farm animals deserve the best possible medicines, and we are committed accelerating innovation in their care. Our approach enables us to bring novel treatments substantially faster to our patients without compromising on safety and efficacy.
Technology
Small molecules
Small molecule pharmaceuticals have been the backbone of medical treatment since the inception of pharmacology. Scientific progress in drug discovery…
Releasing the potential of pharmaceuticals in animal health
Animol Discovery, based on the pioneering work of our exclusive partners X-Chem and ZebiAI, has developed a platform that is unique in the Animal Health industry…
Latest news updates
-
28 Jul 2022Animol Discovery, Inc. announces Series B financing of $34.0 million to advance its pipeline of novel veterinary pharmaceuticals
Financing round led by Novalis LifeSciences LLC Marijn Dekkers, former CEO of Bayer AG, to join the Board of Directors Douglas Hutchens, former Head of Drug Discovery & External Innovation, Global Development & Chief Veterinary Officer, Bayer Animal Health, joining as Chief Scientific Officer Boston, MA- July 28, 2022 – Animol Discovery, Inc., a pioneer in veterinary pharmaceutical discovery, today announced it has raised $34.0 million in Series B financing. The investment was led by Novalis Lifesciences, with participation from Finistere Ventures and existing investor Anterra Capital. The proceeds allow the company to expand and advance its pipeline of novel…
-
15 Mar 2021Former Head Of Business Development, Alliances And Solutions At Zoetis, Michelle Haven, Joins Animol Discovery Board Of DirectorsAnimol Discovery, a biotechnology company delivering break-through novel small molecule drugs for the animal health industry based on its unique technology platform, announced today that Michelle Haven has joined the company’s Board of Directors. Dr. Haven, currently Senior Adviser and Venture Partner at Anterra Capital, comes to Animol with more than 25 years of experience in the animal health industry, most recently as Senior Vice President for Business Development, Alliances and Solutions at Zoetis, Inc. Prior to that, she led global pharmaceutical and biological research at Pfizer Animal Health for several years and contributed to the development of multiple successful products.
-
01 Jan 2020Animol Discovery Announces $6 Million Series A Financing From Anterra Capital To Build High Value Pipeline Of Break-through Small Molecules For Animal HealthAnimol Discovery, Inc. today announced receiving $6 million in seed financing from Anterra Capital to identify and develop its own pipeline of break-through proprietary veterinary small molecules. Based on a unique platform of DNA-encoded libraries (DEL) in combination with advanced machine learning/AI, Animol will deliver unprecedented number of novel compounds in the areas of antiparasitics and therapeutics. Over the coming year Animol Discovery will identify and subsequently develop medicines for companion animals and livestock, either by itself or in cooperation with Animal Health companies.